MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that its corporate presentation will be webcast live during the Seventh Annual JMP Securities Research Conference on Monday, May 19, 2008 at 11:30 a.m. Eastern Time and at the Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 2:00 p.m. Eastern Time.
The JMP presentation will be webcast from The Ritz-Carlton Hotel in San Francisco. To access the live presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at http://www.wsw.com/webcast/jmp6/alxa/.
The Citi Investment will be webcast from the Hilton New York Hotel in San New York. To access the live presentation via the Web, please go to the Investor Relations tab at http://www.alexza.com or at http://www.veracast.com/webcasts/citigroup/healthcare08/31112361.cfm.
A replay of each webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT: Thomas B. King, President & CEO of Alexza Pharmaceuticals, Inc.,
+1-650-944-7634, tking@alexza.com
Web site: http://www.alexza.com//
